Wedbush reiterates Outperform on Xenon Pharmaceuticals, $55 PT
Wedbush maintained an Outperform rating on Xenon Pharmaceuticals and set a $55.00 price target, implying 4.1% downside versus the Sep 17 close of $57.35.
Story updates
01:54:59 PM UTC
SquawkNews
RBC Capital maintained their Outperform rating on Xenon Pharmaceuticals's stock with a price target of $70.00.The price target implies an upside of 22.1% from the Sep 17 close of $57.35.Key takeaways from the analyst noteImpressive Clinical Data: Xenon Pharmaceuticals has demonstrated strong effica…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.